Immune Tolerance
30
2
4
12
Key Insights
Highlights
Success Rate
86% trial completion
Clinical Risk Assessment
Based on trial outcomes
High Risk
Score: 62/100
6.7%
2 terminated out of 30 trials
85.7%
-0.8% vs benchmark
7%
2 trials in Phase 3/4
25%
3 of 12 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 12 completed trials
Clinical Trials (30)
Immune Tolerance Induction After Liver Transplantation
Mechanisms of Maternal Immune Tolerance in Early Pregnancy
TRAnscriptional Profile of Peripheral Blood Cells in Patient With Chronic Kidney and Lung Rejection: Correlation With Response to Extracorporeal Photo-aphereSiS
Improving KIdney Transplantation with Cellular Therapy Study
Andosan in Allergic and Asthma Patients
Long-term Safety Follow-up in Recipients Who Previously Received Medeor's Cellular Immunotherapy Products
Immune Tolerance After Pediatric Liver Transplantation
Efficacy and Safety of Immunosuppressive Withdrawal After Pediatric Liver Transplantation
Preventing Inhibitor Recurrence Indefinitely
Clinico-immunological Characterization and Immune Tolerance Breakdown in HU-autoimmunity
Immune Responses With Reduxium
Kidney and Hematopoietic Cell Transplants Using a Regimen to Promote Hematopoietic Cell Engraftment
Delayed Blood Stem Transplantation in HLA Matched Kidney Transplant Recipients to Eliminate Immunosuppressive Drugs.
The Correlation Between Immunological Reaction of the Seminal Fluid in the Mother's Blood and Pregnancy Complications
Immune Response to BCG Vaccination in Neonates Born to HIV and LTBI Infected and Non-infected Mothers
Liver Immune Tolerance Marker Utilization Study
Kidney and Blood Stem Cell Transplantation That Eliminates Requirement for Immunosuppressive Drugs
Effect of Intralymphatic Immunotherapy
Inducing Graft Tolerance in HLA Haplotype Matched Related and 3 Ag Matched Unrelated Living Donor Kidney Transplantation
Origin of CEC in Patients After Allo-HSCT